Smith & Nephew SNATS (SNN) recently announced an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) – the world's largest, fully integrated, musculoskeletal value-based care and outcomes management company. The collaboration is likely to enhance solutions for Ambulatory Surgical Center's (ASC) customers, physicians, and patients through HOPCo's digital health and analytics platforms, myrecovery and Vitals. More on the Partnership Smith & Nephew is loo ...

Core Insights - Smith+Nephew has announced an exclusive collaboration with Healthcare Outcomes Performance Company (HOPCo) to enhance digital health solutions for ambulatory surgical center (ASC) customers, physicians, and patients [1][8] - The partnership aims to integrate HOPCo's advanced analytics and digital platforms, myrecovery® and Vitals®, with Smith+Nephew's CORI Surgical System to improve surgical planning and patient outcomes [2][14] Company Overview - Smith+Nephew is a global medical technology company founded in 1856, operating in over 100 countries, and generating annual sales of $5.5 billion in 2023 [11][16] - The company focuses on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore patients' bodies and self-belief through innovative technology [16] Collaboration Details - The collaboration will leverage HOPCo's data-driven insights and analytics to enhance the capabilities of the CORI Surgical System, providing surgeons with improved analytics for personalized surgical planning and decision-making [2][14] - HOPCo's myrecovery platform will utilize patient engagement tools and provide critical quality outcome metrics, while the Vitals platform will offer analytics and dashboards to improve care coordination and efficiency [14][15] Strategic Importance - This partnership underscores Smith+Nephew's commitment to advancing orthopedic surgery through innovative technology, aiming to improve patient outcomes and transform healthcare delivery [8][15] - The integration of HOPCo's solutions is expected to unlock value in the ASC segment by utilizing remote therapeutic monitoring (RTM), patient-reported outcomes (PROMs), and analytics to drive efficiencies [8][14]

Core Viewpoint - Smith & Nephew (SNN) is currently identified as a strong value stock with a favorable Zacks Rank of 2 (Buy) and an A for Value, indicating it may be undervalued compared to its peers [2][3]. Valuation Metrics - SNN has a Forward P/E ratio of 14.87, significantly lower than the industry average of 20.26, suggesting potential undervaluation [2]. - The stock's Forward P/E has fluctuated between a high of 17.45 and a low of 11.69 over the past year, with a median of 13.91 [2]. - The PEG ratio for SNN stands at 1.13, compared to the industry average of 2.07, indicating a favorable growth outlook relative to its price [4]. - SNN's PEG ratio has ranged from a high of 1.60 to a low of 0.98 in the past year, with a median of 1.27 [4]. - The P/B ratio for SNN is 2.38, which is attractive when compared to the industry average of 6.95, further supporting the notion of undervaluation [6]. - Over the last 12 months, SNN's P/B has varied from a high of 2.61 to a low of 1.80, with a median of 2.19 [6]. Investment Strategy - The Zacks Style Scores system identifies stocks with specific traits, and SNN's strong Value grade and high Zacks Rank position it among the top value stocks currently available [5]. - Value investing remains a popular strategy, focusing on metrics and fundamental analysis to identify undervalued companies [7].

UHS' earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Smith & Nephew SNATS (SNN) recently announced the receipt of FDA 510(k) clearance for its new CATALYSTEM Primary Hip System. The system is made to meet the changing needs of primary hip surgery, such as the growing popularity of anterior approach procedures and the growing significance of ambulatory surgery centers. More on the CATALYSTEM System The design of CATALYSTEM facilitates accurate fit ...

Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the United States Food and Drug Administration. The system is designed to address the evolving demands of primary hip surgery including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs). Building on the heritage of Smith+Nephew's clinically successful stem designs,3,4 the CATAL ...

Activist Commentary: Cevian Capital, founded in 2002, is an international investment firm acquiring significant ownership positions in publicly listed European companies, where long-term value can be enhanced through active ownership. Cevian Capital is a long-term, hands-on owner of European-listed companies. It is often called a "constructive activist" and is the largest and most experienced dedicated activist investor in Europe. Cevian's strategy is to help its companies become better and more competitive ...

Price Performance SNN carries a Zacks Rank #4 (Sell) at present. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Smith & Nephew SNATS (SNN) is likely to witness operational improvements in the future as Cevian Capital, a Swedish investment firm, purchased a 5% stake in the company. Per the Securities and Exchange Commission disclosure, Cevian Capital now ...

Core Viewpoint - Smith+Nephew announces its sponsorship of tennis players at The Championships, Wimbledon 2024, to highlight its advanced Sports Medicine portfolio and commitment to helping individuals recover from injuries and return to their passions [1][9]. Company Overview - Smith+Nephew, founded in 1856 in Hull, UK, operates in over 100 countries and generated annual sales of $5.5 billion in 2023 [4]. - The company focuses on the repair, regeneration, and replacement of soft and hard tissue, aiming to restore individuals' bodies and self-belief through innovative technologies [12]. Sports Medicine Portfolio - Smith+Nephew offers advanced solutions for common tennis injuries, such as rotator cuff tears and meniscus tears, supported by clinical evidence [7]. - The REGENETEN Bioinductive Implant, introduced in 2014, has been used in over 100,000 procedures globally, positively impacting more than 1 million patients annually undergoing rotator cuff surgery [8]. - The FASTFIX Family of meniscal repair solutions has a 30-year legacy, with an 88% mean success rate for all-inside repairs, helping patients recover effectively [8]. Sponsorship Significance - The sponsorship aligns Smith+Nephew with elite athletes, reinforcing its position as a leader in Sports Medicine technology [9]. - The company aims to support athletes in achieving peak performance and recovery through its innovative product offerings [9].

The Good Brigade/DigitalVision via Getty Images Fourth Quarter Results1,2 Revenue Full Year Results1,2 Revenue Operating profit Operating profit margin (%) EPS (cents) Trading profit Trading profit margin (%) EPSA (cents) Medical devices and supplies manufacturer Smith & Nephew (NYSE:SNN) (OTCPK :SNNUF) has had an underwhelming several years, but at its core is a well- positioned business in a business area with premium pricing and long-term growth prospects. My last piece on the name was September 2022's S ...

So in summary, a solid performance in Q1, despite the expected phasing headwinds. Much of the business is performing strongly, OUS recon, Pharma & Extremities, Sports Medicine Joint Repair and negative pressure wound therapy. As we move through Q2, our collective focus remains on addressing the remaining areas of weakness in US Knees and Hips and on driving further operational and financial improvements across the business. So thank you for listening. With that, I'll hand you back to the moderator for Q&A. ...